OncoMatch/Clinical Trials/NCT01913106
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
Is NCT01913106 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies HSV-tk +Valacyclovir in Combination with Brachytherapy for prostatic neoplasms.
Treatment: HSV-tk +Valacyclovir in Combination with Brachytherapy — The purpose of this study is to conduct a Phase I - II clinical trial to extend preclinical studies involving in situ HSV-tk + Valacyclovir gene therapy in combination with brachytherapy for recurrent prostate cancer. This will provide a novel therapeutic approach to prostate cancer and hopefully impact on the development of metastatic disease and the control of preexisting metastasis.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Performance status
ZUBROD 0–1
Demographics
Prior therapy
Must have received: hormonal therapy — after completion of definitive radiation therapy
after the hormone therapy at least 2 year after the completion of definitive radiation therapy
Must have received: definitive radiation therapy
completion of definitive radiation therapy
Cannot have received: experimental therapeutic cancer treatment
Not on any other experimental therapeutic cancer treatment
Lab requirements
Blood counts
WBC ≥ 4,000/μl, platelets ≥ 100,000/μl, hemoglobin ≥ 8.5 mg/dl, normal partial thromboplastin time and prothrombin time
Kidney function
Serum creatinine ≤ 1.6 mg/dl
Liver function
bilirubin < 1.5 mg/dl, AST and alanine aminotransferase < 2.5 times the upper limit of normal
WBC ≥ 4,000/μl, platelets ≥ 100,000/μl, hemoglobin ≥ 8.5 mg/dl, normal partial thromboplastin time and prothrombin time, bilirubin < 1.5 mg/dl, AST and alanine aminotransferase < 2.5 times the upper limit of normal, Serum creatinine ≤ 1.6 mg/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Houston Methodist · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT01913106 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior experimental therapeutic cancer treatment disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages